Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Carina Mina Abrahao"'
Autor:
Aline Da Rocha Lino, Carolina Kawamura Haddad, Tarcia Tarciane Soares de Sousa, Rafael Ferreira de Carvalho, Renata D'Alpino Peixoto, Marcus Paulo Fernandes Amarante, Fernando C. Maluf, Carina Mina Abrahao, Antonio C. Buzaid, Matheus Bongers Alessandretti, Coaem, Jessica Ribeiro Gomes, Fabio A.B. Schutz, Rodnei Merlrina Martins Junior, Raphael Brandao Moreira, Marcelo Rocha Cruz
Publikováno v:
Journal of Clinical Oncology. 33:72-72
72 Background: A considerable number of patients with mGIC progress after exhausting all approved standard therapies but maintain an adequate performance status and could be candidates for further treatment. We aim at reviewing our experience with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00b7804dc65fbd98ac92bdea541230e2
https://doi.org/10.1200/jco.2015.33.3_suppl.72
https://doi.org/10.1200/jco.2015.33.3_suppl.72
Autor:
Jessica Ribeiro Gomes, Aline Da Rocha Lino, Carolina Kawamura Haddad, Carina Mina Abrahao, Antonio C. Buzaid, Matheus Bongers Alessandretti, Tarcia Tarciane Soares de Sousa, Fernando C. Maluf, Renata D'Alpino Peixoto, Rodnei Merlrina Martins Junior, Raphael Brandao Moreira, Marcus Paulo Fernandes Amarante, Marcelo Rocha Cruz
Publikováno v:
Journal of Clinical Oncology. 33:315-315
315 Background: Metastatic PA is a lethal malignancy with poor prognosis and limited therapeutic options. We hypothesized that a comprehensive next-generation sequencing (NGS) assay could identify novel therapy targets not routinely explored in PA pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39f0165cdf2d079bdaf4655170d9f3eb
https://doi.org/10.1200/jco.2015.33.3_suppl.315
https://doi.org/10.1200/jco.2015.33.3_suppl.315
Autor:
Aline Da Rocha Lino, Tarcia Tarciane Soares de Sousa, Jessica Ribeiro Gomes, Carolina Kawamura, Matheus Bongers Alessandretti, Marcelo Rocha Cruz, Fernando C. Maluf, Carina Mina Abrahao, Antonio C. Buzaid, Renata D'Alpino Peixoto, Rafael Schmerling, Rodnei Merlrina Martins Junior, Raphael Brandao Moreira, Marcus Paulo Fernandes Amarante, Fabio A.B. Schutz
Publikováno v:
Journal of Clinical Oncology. 33:216-216
216 Background: Despite a large number of randomized trials, there is no consensus as to the best regimen for advanced gastroesophageal cancer. Combination therapy with docetaxel, cisplatin, and 5-FU has shown increased response rates, progression-fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0ac3ea1d3044c1d510d6ad846dcccec
https://doi.org/10.1200/jco.2015.33.3_suppl.216
https://doi.org/10.1200/jco.2015.33.3_suppl.216
Autor:
Carolina Kawamura, Fernando C. Maluf, Carina Mina Abrahao, Andrea Malta Ferrian, Aline Da Rocha Lino, Antonio C. Buzaid, Renata D'Alpino Peixoto, Marcelo Rocha Cruz, Jessica Ribeiro Gomes, Tarcia Tarciane Soares de Sousa, Marcus Paulo Fernandes Amarante, Rafael Schmerling, Matheus Bongers Alessandretti, Marcel Cerqueira Cesar Machado, Rodnei Merlrina Martins Junior, Raphael Brandao Moreira, Fabio A.B. Schutz
Publikováno v:
Journal of Clinical Oncology. 33:473-473
473 Background: Cancer of the exocrine pancreas is a highly lethal malignancy. Based on a phase III study, FOLFIRINOX regimen became the standard first-line treatment for patients with good performance status. However, the optimal management strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d839253a8b8b781ff32950912b1a17dc
https://doi.org/10.1200/jco.2015.33.3_suppl.473
https://doi.org/10.1200/jco.2015.33.3_suppl.473
Autor:
Matheus Bongers Alessandretti, Raphael Brandao Moreira, Erika Pereira Brandao, Jessica Ribeiro Gomes, Marcus Paulo Fernandes Amarante, Aline Da Rocha Lino, Rodnei Merlrina Martins Junior, Carina Mina Abrahao, Tarcia Tarciane Soares de Sousa, Renata D'Alpino Peixoto, Marcelo Rocha Cruz, Fernando C. Maluf, Antonio C. Buzaid
Publikováno v:
Journal of Clinical Oncology. 33:468-468
468 Background: There is only limited data regarding efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma. We aim to evaluate our experience with dose-reduced FOLFIRINOX in patients > 65 years-old. Methods: Al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcb3e36d6c11d8e925ae1600f1120b49
https://doi.org/10.1200/jco.2015.33.3_suppl.468
https://doi.org/10.1200/jco.2015.33.3_suppl.468